Novartis to buy immunotherapy start-up

|About: Novartis AG (NVS)|By:, SA News Editor

Novartis (NVS) has agreed to acquire CoStim Pharmaceuticals, which focuses on using the immune system to battle cancer.

Terms of the deal weren't disclosed.

Immunotherapy is one of the hottest areas of cancer research, with Merck, AstraZeneca and Bristol-Myers among those working in the field. (PR)